A life course approach to cardiovascular disease prevention

European Journal of Cardiovascular Nursing

Volumn 10, Issue SUPPL. 2, 2011, Pages

  Hayman, Laura L ^a   Helden, Liz ^b   Chyun, Deborah A ^c   Braun, Lynne T ^d  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b MCMASTER CHILDREN S HOSPITAL   (Canada)

^c NEW YORK UNIVERSITY   (United States)

^d RUSH UNIVERSITY COLLEGE OF NURSING   (United States)

Author keywords

CVD; Life course; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; INFLUENZA VACCINE; OMEGA 3 FATTY ACID; SIMVASTATIN; VEGETABLE OIL;

ARTICLE; ATHEROSCLEROSIS; AUTOPSY; BODY MASS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL PROTOCOL; COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY RECANALIZATION; DIET THERAPY; DIETARY INTAKE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; EVIDENCE BASED PRACTICE; HEALTH PROMOTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; IN VIVO STUDY; INFLUENZA VACCINATION; ISCHEMIC HEART DISEASE; LIFE EVENT; LIFESTYLE MODIFICATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; OBESITY; OVERALL SURVIVAL; PATHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; HEALTH PROMOTION; HUMANS; LIFE STYLE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; WORLD HEALTH;

EID: 79960290561     PISSN: 14745151     EISSN: 18731953     Source Type: Journal    
DOI: 10.1016/S1474-5151(11)00113-7     Document Type: Article

References (79)

1. Halfon N, Holstein M Life course health development: an integrated framework for developing health, policy and research. Milbank Q 2002, 80(3):433-479.
2. Ben-Shlomo Y, Kuh D A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol 2002, 31(2):285-293.
3. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003, 107(4):1562-1566.
4. Daniels SR, Greer FR, the Committee on Nutrition Lipid screening and cardiovascular health in childhood. Pediatrics 2008, 122(1):198-208.
5. Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation 2009, 119:1161-1175.
6. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med 1998, 338(23):1650-1656.
7. McGill HC, McMahan CA, Malcom GT, Oalmann MC, Strong JP Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vase Biol 1995, 15(9):512-1531.
8. McGill HC, McMahan CA, Malcom GT, Oalmann MC, Strong JP, the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vase Biol 1995, 15:431-440.
9. Davis PH, Dawson JD, Riley WA, Lauer RM Carotid intimal-media thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation 2001, 104:2815-2819.
10. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003, 290(17):2271-2276.
11. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003, 290(17):2277-2283.
12. Urbina EM, Kimball TR, McCoy CE, Khoury PR, Daniels SR, Dolan LM Youth with obesity and obesity-related type 2 diabetes mellitus demonstrate abnormalities in carotid structure and function. Circulation 2009, 119(22):2913-2919.
13. Lauer RM, Clarke WR Use of cholesterol measurements in childhood for the prediction of adult hypercholesterolemia: the Muscatine Study. JAMA 1990, 264(23):3034-3038.
14. Webber LS, Srinivasan SR, Wattigney WA, Berenson GS Tracking of serum lipids and lipoproteins from childhood to adulthood; the Bogalusa Heart Study. Am J Epidemiol 1991, 133(9):884-899.
15. Riddoch C, Edwards D, Page A, et al. The European Youth Heart Study. Cardiovascular disease risk factors in children: rationale, aims, design, and validation of methods. J Phys Act Health 2005, 2:115-129.
16. Porkka KV, Viikari JS, Taimela S, Dahl M, Akerblom HK Tracking and predictiveness of serum lipid and lipoproteins measurements in childhood: a 12-year follow-up: the Cardiovascular Risk in Young Finns study. Am J Epidemiol 1994, 140(12):1096-1110.
17. Lee DS, Chiu M, Manuel DG, Canadian Cardiovascular Outcomes Research Team, et al. Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors. CMAJ 2009, 181(3-4):E55-E66.
18. Paradis G, Lambert M, O'Loughlin J, et al. The Quebec Child and Adolescent Health and Social Survey: design and methods of a cardiovascular risk factor survey for youth. Can J Cardiol 2003, 19(5):523-531.
19. Janssen I, Katzmarzyk PT, Boyce WF, Health Behavior in School-Aged Children Obesity Working Group, et al. Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationships with physical activity and dietary patterns. The International Association for the Study of Obesity. Obes Rev 2005, 6(2):123-132.
20. Caprio S, Bronson M, Sherwin RS, Rife F, Tamborlane WV Coexistence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children. Diabetologia 1996, 39(12):1489-1497.
21. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemio-logic review and a public health perspective. J Pediatr 2000, 136(5):664-672.
22. Gidding SS Dyslipidemia in the metabolic syndrome in children. J Cardiometab Syndr 2006, 1(4):282-285.
23. Hansen ML, Gunn PW, Kaelber DC Underdiagnosis of hypertension in children and adolescents. JAMA 2007, 298(8):874-879.
24. Steinberger J, Daniels SR, Eckel R, et al. Progress and challenges in the metabolic syndrome in children and adolescents. Circulation 2009, 119(4):628-647.
25. Lau D, Douketis J, Morrison KM, Hramiak I, Sharma A, Ur E Expert panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children: summary report. CMAJ 2007, 176(suppl 8):S1-S13.
26. Barlow SE, for the Expert Committee Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent, overweight and obesity: summary report. Pediatrics 2007, 20(suppl 4):S164-S192.
27. Morrison KM, Atkinson SA, Yusuf S, FAMILY Investigators, et al. The Family Atherosclerosis Monitoring In earLY life (FAMILY) study: rationale, design, and baseline data of a study examining the early determinants of atherosclerosis. Am Heart J 2009, 158(4):533-539.
28. Olsen J, Melbye M, Olsen SF, et al. The Danish national birth cohort - its background, structure and aim. Scand J Public Health 2001, 29(4):300-307.
29. Reilly JJ, Armstrong J, Dorosty AR, et al. Early life risk factors for obesity in childhood: cohort study. BMJ 2005, 330(7504):1357-1364.
30. National Institutes of Health. National Heart, Lung, and Blood Institute. NHLBI Pediatric Guidelines for Cardiovascular Health Promotion and Risk Reduction. 2010. In press.
31. A Race Against Time. The Challenge of Cardiovascular Disease in Developing Economies Accessed June 18, 2010. http://www.earth.columbia.edu/news/2004/images/raceagainsttime_FINAL_051104.pdf.
32. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
33. Greenberg H, Raymond SU, Leeder SR Cardiovascular disease and global health: threat and opportunity. Health Affairs Web Exclusive 2005;W5-31-4l Accessed June 20, 2010. http://content.healthaffairs.org.ezproxy.lib.umb.edu/cgi/reprint/hlthaff.w5.31vl.
34. Reddy KS India wakes up to the threat of cardiovascular diseases. J Am Coll Cardiol 2007, 50(14):1370-1372.
35. American Heart Association Heart disease and stroke statistics: 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):e21-e81.
36. Grundy SM, Cleeman JI, Merz CNB, for the Coordinating Committee of the National Cholesterol Education Program, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110(2):227-239.
37. Nakamura H, Arakawa K, Itakura H, for the MEGA Study Group, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet 2006, 368(9540):1155-1163.
38. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000, 356(9246):1955-1964. Blood Pressure Lowering Treatment Trialists' Collaboration.
39. United Nations World Population Prospects: The 2002 Revision (Medium Scenario) 2003, United Nations Publication, New York, NY.
40. United Nations. World Population Prospects: The 2004 Revision. United Nations Publication; 2005.
41. United Nations. Population Challenges and Development Goals. United Nations Publication; 2005. Sales No. E.05.XIII.8.
42. Department of Economic and Social Affairs UN Secretariat. The Diversity of Changing Population Age Structures in the World 2005, Department of Economic and Social Affairs Population Division, New York, NY.
43. Population Reference Bureau Staff. Popul Bull 2004, 59.
44. The impact of cardiovascular risk factors on the age-related excess of coronary heart disease. Int J Epidemiol 2006, 35(4):1025-1033. Asia Pacific Cohort Studies Collaboration.
45. Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007, 25(l):73-79. for the Asia-Pacific Cohort Studies Collaboration.
46. Sasayama S Heart disease in Asia. Circulation 2008, 118:2669-2671.
47. Ford ES, Giles WH, Dietz WH Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287(3):356-359.
48. Vita AJ, Terry RB, Hubert HB, Fries JF Aging, health risks, and cumulative disability. N Engl J Med 1998, 338(15):1035-1041.
49. Gill TM, Baker DI, Gottschalk M, Gahabuer EA, Charpentier PA, de Regt PT A rehabilitation program for physically frail community-living older persons. Arch Phys Med Rehabil 2003, 84(3):394-404.
50. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes meilitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119(13):1728-1735.
51. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the 4S study. Circulation 1997, 96(12):4211-4218.
52. LaRosa JC, He J, Vupputuri S Effects of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282(24):2340-2346.
53. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events Trial (CARE). Ann Intern Med 1998, 129(9):681-689.
54. LIPID Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339(19):1349-1357.
55. Diabetes Prevention Program Research Group Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346(6):393-403.
56. Yusuf S, Hawken S, Óunpuu S, the INTERHEART Study Investigators, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEARTstudy): case-control study. Lancet 2004, 364(9438):937-952.
57. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005, 112(22):3384-3390. Asia Pacific Cohort Studies Collaboration.
58. de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham Risk Score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 2008, 337:a3083. 10.1136/bmj.a3083.
59. Williams MA, Heg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients >75 years of age). Circulation 2002, 105(14):1735-1743.
60. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial. Lancet 2002, 360(9346):1623-1630.
61. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358(18):1887-1898.
62. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002, 106(3):388-391.
63. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, the Stroke Association JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, 91(suppl V):v1-v52.
64. Lloyd-Jones DM Cardiovascular risk prediction: basic concepts, current status and future directions. Circulation 2010, 121:1768-1777.
65. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
66. D'Agostino RB, Grundy SM, Sullivan LM, Wilson P, for the CHD Risk Prediction Group Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187.
67. Brindle P, May M, Gill P, et al. Primary prevention of cardiovascular disease: a Web-based risk score for seven British black and minority ethnic groups. Heart 2006, 92(11):1595-1602.
68. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation 2008, 117(6):743-753.
69. Assmann G, Cullen P, Schulte H Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 2002, 105:310-315.
70. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P Derivation and validation of QRISK a new cardiovascular risk score for the United Kingdom: prospective open cohort study. BMJ 2007, 335(7611):136.
71. Ridker PM, Buring JE, Rifai N, Cook NR Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007, 297:611-619.
72. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR C-reactive protein and parental history improve global risk prediction: the Reynolds score for men. Circulation 2008, 118:2243-2251.
73. New Zealand Guidelines Group New Zealand Cardiovascular Guidelines Handbook: A Summary Resource for Primary Care Practitioners 2009, New Zealand Guidelines Group, Wellington, New Zealand. 2nd ed.
74. Conroy RM, Pyorala K, Fitzgerald AP, SCORE Project Group, et al. Estimation of ten year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24(11):987-1003.
75. Lloyd-Jones DM, Wilson PWF, Larson MG, et al. Framingham Risk Score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004, 94(l):20-24.
76. Lloyd-Jones DM, Larson MG, Beiser A, Levy D Lifetime risk of developing coronary heart disease. Lancet 1999, 353(9147):89-92.
77. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113(6):791-798.
78. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006, 113(19):2363-2372.
79. Mosca L, Benjamin E, Berra K, et al. Evidence-based guidelines for the prevention of cardiovascular disease in women 2011 update: a guideline from the American Heart Association, [published online ahead of print February 16, 2011]. Circulation 2011, 123:1243-1262.